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Abstract
Background: Invasive fungal infections (IFI) are associated with considerable expense and mortality on healthcare
systems. There is a need to provide evidence of both clinical efficacy and value for money with any health
technology. The current pharmacoeconomic evaluation investigated the use of liposomal amphotericin B (LAmB)
and voriconazole for the empiric treatment of IFI in the Turkish setting.
Methods: Decision analytic modelling was used to create a pathway for patient treatment with a 5-point composite
outcome measure. The data was obtained from a major non-inferiority multicentre randomised controlled study, with
an expert panel of clinicians in Turkey providing transition probabilities and cost not available in the literature. Sensitivity
analyses were performed on the inputs from the clinical trial and the expert panel.
Results: As per the base case analysis, voriconazole was preferred by Turkish Lira (TL) 2,523 per patient treated and
TL2,520 per surviving patient. LAmB was the preferred alternative by TL5,362 per successfully treated patient. Removing
fever resolution as part of the composite outcome measure resulted in voriconazole being the preferred alternative per
successfully treated patient. Univariate sensitivity analysis highlighted that increasing the duration of voriconazole
by >1.2 days or decreasing LAmB by >1.0 days changes the result. Monte Carlo Simulation resulted in 69.4% of
simulations favouring voriconazole per patient treated.
Conclusion: There is a strong likelihood that voriconazole is economically more favourable than LAmB in the empiric
treatment of IFI in Turkey.
Keywords: Antifungal agents, Voriconazole, Liposomal amphotericin B, Economic evaluation, Invasive fungal infection,
Empiric therapy
Background
Invasive fungal infections (IFIs) are predominantly an ad-
verse outcome associated with an immunocompromised
health state [1]. This is often encountered in prolonged
neutropenia resulting from chemotherapy treatments [1].
Indeed, the cost to the healthcare systems for treating IFIs
(including antifungal medications, extended hospital stays
and other monitoring costs) are of significant concern [2,3].
Liposomal amphotericin B (LAmB) has been a main-
stay in the empiric treatment of IFI [4,5]. Other agents
include echinocandins such as micafungin, caspofungin
and anidulafungin, and azoles such as voriconazole (des-
pite voriconazole having not been approved for empiric
use to date) [6-9]. Significantly, all currently used anti-
fungal agents are costly, with the treatment duration be-
ing upwards of 1-2 weeks [2].
There are previous economic evaluations of voricona-
zole and LAmB [10-12]. The majority of these studies
highlighted voriconazole as the preferred option. It is
important to highlight, however, that the choice of the
methodology in these studies may have influenced the
conclusion reached. The single study that found LAmB
to be economically favourable utilized a model that
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described treatment beyond the first-line empiric therapy
by including alternative scenarios [10]. Other studies have
focused on specific antifungal-associated adverse effects,
or have used chart review information from a single site as
opposed to multi-site data from generalizable sources
[11,13]. Of note is that the economic impact of the anti-
fungal agent alone (i.e. drug acquisition cost) does not
necessarily reflect the overall relative cost of treatment
from a cost-effectiveness perspective, as this requires in-
clusion of both efficacy data as well as other cost categor-
ies [14]. Importantly, economic conclusions are usually
not generalizable between countries with different health-
care systems, reimbursement policy and/or standard of
care.
The objective of the current study is to determine the
cost-effectiveness of voriconazole and LAmB from the
Turkish healthcare perspective. The Turkish healthcare
system is significantly disparate in functioning and eco-
nomics to those studied in earlier evaluations. Currently,
there are no economic studies which will guide the choice
between use of these two agents in the Turkish healthcare
or other systems similar to the Turkish settings. As such,
an evaluation of voriconazole and LAmB in the empiric
treatment of IFI would be useful in providing guidance to
clinicians and decision makers working in these settings,
with respect to the economic consequences of using these
agents.
Methods
This cost-effectiveness evaluation was constructed using
the data from a multicentre, international randomized-
controlled non-inferiority study investigating the efficacy
and safety of voriconazole vs. LAmB in empiric treatment
of IFIs by Walsh et al [3]. The study randomized 415 pa-
tients to receive voriconazole and 422 patients to LAmB.
Successful treatment was defined using a five-component
end point that included: successful treatment of any base-
line fungal infection (diagnosed within 24 hours of initi-
ation into the study), absence of a breakthrough fungal
infection during therapy (or seven days after completion
of therapy), survival for seven days after treatment, no pre-
mature discontinuation of therapy, and resolution of fever
during the period of neutropenia [3].
Perspective
The Turkish healthcare system’s perspective was
adopted, focusing on direct medical costs from medica-
tions related to the empiric treatment of an IFI,
hospitalization costs, monitoring and screening tests.
Staff wages and costs associated with treating the
underlying patient conditions (such as acute myeloid
leukaemia) were not included. The time horizon was
that used in the Walsh study i.e. up to 7 days beyond
the end of therapy [3].
Model structure
The decision-analytic tree outlining the usual treatment
algorithm for patients receiving either voriconazole or
LAmB was based on work of Al-Badriyeh et al. [10] This
tree (Figure 1) allowed for 8 distinct patient outcomes
stratified on the presence or absence of a baseline fungal
infection; incorporating the 5-point composite outcome
measure previously referenced. Those patients with no base-
line fungal infection will fall into branches describing either
successful treatment from the antifungal agent chosen, or
failure resulting in either mortality or distinct outcomes re-
quiring a transition to an alternative agent (breakthrough
fungal infection, premature discontinuation or persistent
fever). Patients with a baseline fungal infection are described
by 3 branches viz. successful treatment, failure resulting in
mortality or a persistent baseline fungal infection necessitat-
ing a transition to an alternative antifungal agent.
Model inputs
Clinical data from the Walsh study (Table 1) were used to
populate the model including the mortality rate of patients
receiving voriconazole and LAmB, the rate of discontinu-
ation due to nephrotoxicity, hepatotoxicity or infusion-
related reactions, as well as the occurrence of baseline
fungal infections [3]. As per the Walsh study, patients re-
ceived either 3 mg/kg LAmB intravenously each day or a
standard dosing of 6 mg/kg voriconazole every 12 hours
for the first two doses then a maintenance dose of 3 mg/
kg every 12 hours (or 200 mg orally every 12 hours, after
at least 3 days of intravenous therapy). An expert panel of
five infectious diseases, haematology and oncology clini-
cians in Turkey provided a consensus opinion on data re-
quired in the model that was not readily available from
published or public sources. Information from the panel
included duration of antifungal therapy; concomitant
medications (related to the antifungal therapy); probability
and duration of intensive care unit (ICU) admission, mon-
itoring and screening test utilization; proportion of pa-
tients receiving a dose increase or decrease of the initial
antifungal agent due to tolerability or lack of efficacy;
distribution of discontinuation events; and the alternative
antifungal agent given in various scenarios following dis-
continuation of the initial antifungal agent (Table 2).
The panel provided consensus opinions that the average
treatment duration for both agents (i.e. voriconazole and
LamB) was 10 days; piperacillin/tazobactam and vanco-
mycin for the full treatment duration and granulocyte
colony-stimulating factor (G-CSF) for the first five days
were given as concomitant therapies; 5 days were spent in
the ICU out of the total treatment duration by 7.5% of pa-
tients; no post-therapy observational period was provided
at the end of a course of treatment; dose changes were not
seen in the Turkish setting due to adverse effects or lack
of efficacy at standard doses, instead a change in
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antifungal agent was the usual course of action; the com-
mon screening tests used during hospitalization included
a chest x-ray at onset of fever and weekly thereafter, com-
puted tomography (CT) scan at one week post identifica-
tion of an unresponsive fever; routine blood cultures and
full blood examination (FBE) repeated daily; renal func-
tion, liver function and electrolyte tests were performed
three times each week; galactomannan assay twice each
week and a single bronchoscopy performed in approxi-
mately two thirds of all patients. This schedule of screen-
ing did not change in the scenario of an ICU admission.
Assumptions
The assumptions made for our model included:
1. Only one treatment failure may be experienced by a
patient which then results in a switch to an alternative
antifungal agent or death. The switch to an alternative
agent will result in a successful outcome.
2. Due to the inability to characterize the population of
patients with baseline fungal infection that had
initial treatment failure in the Walsh study [3], all
patients in this branch were assumed to survive with
persistent unresolved fever.
3. A patient with a baseline fungal infection has the
same risk of discontinuation as those with no
baseline fungal infections.
4. Mortality and discontinuation events occur at the
end of a course of therapy.
Cost calculations
Costs used were sourced from Sosyal Güvenlik Kurumu
(SGK) in Turkey [15]. All costs were reported in 2012
Turkish Lira (TL). To determine the average daily cost
of the antifungal medications, an average patient weight
Figure 1 Decision tree for the empiric treatment of IFI with voriconazole or liposomal amphotericin B in adult febrile neutropaenic patients.
Table 1 Clinical outcome data of Voriconazole vs. LAmB
for use in decision model [3]
Variable Voriconazole LAmB
Fever with no baseline fungal infection 96.87% 98.58%
Therapeutic success 25.37% 30.05%
Therapeutic failure 74.63% 69.95%
Mortality 11.00% 8.59%
Breakthrough fungal infection 2.67% 7.22%
Premature discontinuation 13.67% 9.62%
Persistent fevera 72.67% 74.57%
Fever with baseline fungal infection 3.13% 1.42%
Therapeutic success 46.15% 66.67%
Therapeutic failure 53.85% 33.33%
aThe number of patients with persistent fever was determined by subtracting
the number of patients that failed therapy due to a reason other than
persistent fever from the total number of patients that had therapeutic failure
to either voriconazole or LAmB.
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of 70 kg was used. This weight was validated by the ex-
pert panel. Discounting was not considered due to the
short time frame.
Specific costs from the SGK included: LAmB 50 mg
vial, TL317; caspofungin 70 mg vial, TL906.99; caspofun-
gin 50 mg vial, TL701.20; voriconazole 200 mg vial,
TL284.92; voriconazole 200 mg tablet, TL35.11; a bottle
of posaconazole suspension, TL1379.60; G-CSF 300 μg
syringe, TL138.50; piperacillin/tazobactam 4.5 g vial,
TL23.00; vancomycin 500 mg vial, TL15.73; chest x-ray
(per test), TL7.98; diphenhydramine 50 mg vial, TL0.57; CT
scan (per test), TL60.50; bronchoalveolarlavage (per lavage),
TL177.07; galactomannan assay (per test), TL42.04; routine
blood cultures (per test), TL11.00; full blood examination
(per test), TL7.18; renal function test (per test), TL10.34;
liver function test (per test), TL11.12; electrolyte test (per
test), TL4.84; non-ICU per diem, TL79.02; ICU per diem,
TL969.52.
For each branch of the decision tree, a weighted average
cost was calculated utilizing the total cost and probability
associated with each branch. For a patient with successful
treatment from the initial antifungal agent, the cost in-
cluded acquisition of the antifungal agent and concomitant
medications, hospitalization, screening and monitoring
tests. In the case of failure resulting in death, the cost was
equivalent to a successful treatment due to the assumption
that any discontinuation and mortality events occur at the
end of a course of treatment. For a patient requiring al-
ternative treatment, the total cost includes cost of the
alternative antifungal agent and concomitant therapy,
hospitalization, screening and monitoring tests, in
addition to the cost from the initial therapy.
To reflect clinical practice, all doses of medications
were rounded to the nearest full vial. Posaconazole,
however, was an exception as it was considered that a
bottle of posaconazole suspension could be realistically
used for multiple patients. In the situation where costs
were provided as a range of options, an average was
taken. As patients could be admitted to either a haem-
atological or bone marrow transplant (BMT) wards, a
weighted average cost was taken between the two
wards, based on the advice of the expert panel as to the
proportion of febrile neutropenic patients that would be
seen in each ward. Similarly, an average across a 5-day
stay in the ICU was taken to reflect the ICU per-diem.
The cost of voriconazole therapeutic drug monitoring
(TDM) and consequences of voriconazole TDM was
not included as the expert panel concluded that vorico-
nazole T DM was rarely performed in the Turkish
healthcare system.
Table 2 Alternative antifungal agents given after treatment failure with Voriconazole or LAmB
Reason for treatment failure Alternative given
Voriconazole arm LAmB arm
Infusion-related reactionsa Caspofunginb Voriconazolec
Nephrotoxicity Caspofunginb Caspofunginb
Hepatotoxicity LAmBd Caspofunginb
Suspected fungal infection LAmBe Voriconazolec
Persistent fever LAmBe Voriconazolec
Breakthrough fungal infection
Aspergillus spp. LAmBd Voriconazolec
Candida spp. Caspofunginb Caspofunginb
Zygomycetes spp. LAmBe N/A
DematiaceousMoulds N/A LAmB plus posaconazolef
Moulds not identified N/A LAmBe
Non-responding baseline fungal infection
Aspergillus spp. LAmBd Voriconazolec
Candida spp. Caspofunginb Caspofunginb
Zygomycetes spp. LAmB plus posaconazolef N/A
Trichoderma fungemia N/A Voriconazolec
Fusarium spp. N/A LAmB plus posaconazolef
Moulds not identified N/A LAmB plus posaconazolef
aA switch to alternative therapy due to infusion-related reactions included commencement of pre-dose diphenhydramine; bCaspofungin dose 70 mg on day one,
50 mg thereafter; cVoriconazole dose 6 mg/kg i.v. twice daily on day one, 4 mg/kg i.v. twice daily or 400 mg p.o. twice daily thereafter (22% in base case received
oral voriconazole); dLAmB dose 3 mg/kg/day; eLAmB 5 mg/kg/day; fLAmB dose 5 mg/kg/day, posaconazole 200 mg four times per day.
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Sensitivity analysis
To determine the model’s robustness, deterministic and
probabilistic sensitivity analyses were performed. Univar-
iate sensitivity analyses were conducted on the duration
of antifungal treatment (min. 6, max. 14 days), propor-
tion of patients receiving oral voriconazole (min. 0%,
max. 50%), proportion of patient utilizing the ICU (min.
5%, max 10%), the daily cost of an ICU bed (min.
TL220, max. TL1420) and inclusion of concomitant
medications in the overall cost calculations . A threshold
analysis based on independent changes on the list price
of the initial antifungal agent and duration of treatment
was also performed. Univariate sensitivity analysis was
conducted to investigate the effect of including/exclud-
ing fever resolution as part of the composite outcome
measure on the final result, as this had been an area of
discussion in recent literature [16,17]. This analysis was
achieved by providing an alternate scenario where those
patients in branches that would have been considered
treatment failures due to persistent fever were instead
rolled into the successful treatment branch.
A Monte-Carlo Simulation (MCS) of 10,000 patients
was performed to allow variation of several inputs
simultaneously, enhancing the study’s generalizability
and reflect a situation closer to a real-life situation
of multiple simultaneous variations from the base
model. The probabilities from the trial by Walsh [3],
as well as data provided by the expert panel regard-
ing treatment duration and hospitalization costs were
mapped to a distribution of plausible alternatives
(Table 3), allowing for a probability of favouring one
agent over the other to be developed through itera-
tions of multiple scenarios.
Results
Compared to LAmB in the base case analysis, voriconazole
was the cost-effective alternative by TL2,523 per patient
treated and TL2,520 per surviving patient. LAmB was the
preferred alternative by TL5,362 per successfully treated
patient. A description of the probability and cost of each
branch of the model is given in Table 4. LAmB had a
higher probability of success and lower mortality than vori-
conazole (30.57% vs. 26.02% and 5.92% vs. 7.95%, respect-
ively) [3]. Whilst initial treatment with LAmB is associated
with higher cost per patient, the cost associated with alter-
natives following treatment failure with LAmB is lower
compared to using voriconazole (TL17,867 vs. TL9,836 in
initial therapy cost and TL5,687 vs. TL11,152 in alternative
therapy cost for LAmB vs. voriconazole). The breakdown
of the cost categories is described in Figure 2.
The only univariate sensitivity analysis that resulted in
a change in the study’s conclusion was in the alternative
scenario created with the exclusion of fever resolution
as part of the composite outcome measure. This re-
sulted in voriconazole being the preferred alternative in
all metrics considered (per patient treated TL13,960 vs.
TL20,916; per successfully treated patient TL17,771 vs.
TL25,511; per patient surviving TL13,971 vs. TL20,929,
for voriconazole vs. LAmB). The change from a 5-point
to a 4-point composite outcome measure also altered
the overall success rate of each agent, from 26.02% to
78.55% for voriconazole and 30.57% to 81.99% for
LAmB. All other one-way analyses did not change the
study’s conclusion, but either slightly contracted or ex-
tended the economic preference for voriconazole. Re-
moval of the cost of concomitant medications from the
analysis also did not alter the study’s conclusion.
Table 3 Input variables and distribution for Monte Carlo simulation sensitivity analyses
Input variable Voriconazole LAmB
Fever without baseline infection Triangular distribution, 92.03%-96.87%-100% Triangular distribution, 93.65%-98.58%-100%
Therapeutic success Triangular distribution, 24.10%-25.37%-26.64% Triangular distribution, 28.55%-30.05%-31.55%
Therapeutic failure Triangular distribution, 70.90%-74.63%-78.36% Triangular distribution, 66.45%-69.95%-73.45%
Death Triangular distribution, 10.45%-11.00%-11.55% Triangular distribution, 8.16%-8.59%-9.02%
Breakthrough infection Triangular distribution, 2.40%-2.67%-2.94% Triangular distribution, 6.50%-7.22%-7.94%
Premature discontinuation Triangular distribution, 12.30%-13.67%-15.04% Triangular distribution, 8.66%-9.62%-10.58%
Persistent fever Triangular distribution, 65.40%-72.67%-79.94% Triangular distribution, 67.11%-74.57%-82.03%
Fever with baseline infection Triangular distribution, 2.97%-3.13%-3.29% Triangular distribution, 1.20%-1.42%-1.49%
Therapeutic success Triangular distribution, 43.84%-46.15%-48.46% Triangular distribution, 63.34%-66.67%-70.00%
Therapeutic failure Triangular distribution, 51.16%-53.85%-56.54% Triangular distribution, 31.66%-33.33%-35.00%
Ward “per diem” Discrete, 30% at TL193.40 and 70% at TL30.00
ICU length of stay Log-normal, mean 5 days, standard deviation 2.5 days
Overall treatment duration Log-normal, mean 10 days, standard deviation 2 days
Proportion of oral voriconazole use Triangular distribution, 0-22-50%
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Threshold analysis suggested the current model is
highly sensitive to a change in treatment duration of ei-
ther antifungal agent. An increase in voriconazole treat-
ment duration by >1.2 days resulted in voriconazole no
longer being the economically favourable option, from a
per patient treated perspective. Likewise, a decrease in
LAmB treatment duration by >1.0 days resulted in LAmB
becoming the favourable alternative. The model was mod-
erately sensitive to changes in drug acquisition costs. Vori-
conazole required an increase in list price of >32.4% or
LAmB a decrease of >15.8% to change the study’s conclu-
sion. Note that the change in list price of the antifungal
agent was taken as an equivalent percentage change for
both the vial and oral formulation of voriconazole (i.e. in
determining the threshold of > 32.4%, both the vial and
oral formulation were altered concurrently). Finally, MCS
highlighted that when considering the two agents from a
per patient treated perspective, there is a 69.4% probability
of the analysis favouring voriconazole (Figures 3 and 4).
Discussion
The current study suggests an economic advantage favour-
ing the use of voriconazole over LAmB in the empiric treat-
ment of febrile neutropenia in the Turkish or related
healthcare settings. A major strength of this study was that
it took into consideration the downstream consequences of
treatment failures. Indeed, this is one of the few studies that
have specifically targeted the choice of alternative antifungal
agent based on the reason for treatment failure and/or or-
ganism cultured [10,18,19]. The use of an expert panel of
Table 4 Cost and proportion of patients for empiric use of Voriconazole vs. LAmB
Outcome Voriconazole LAmB
Proportion (%) Cost (TL) Proportionate
cost (TL)*
Proportion (%) Cost (TL) Proportionate
cost (TL)*
No baseline fungal infection
Successful treatment 24.58 11,551 2,839 29.62 19,492 5,774
Mortality 7.95 11,551 919 5.92 19,492 1,155
Breakthrough fungal infection 1.93 29,777 574 4.98 31,593 1,572
Premature discontinuation 9.88 30,179 2,982 6.64 29,784 1,976
Persistent fever 52.53 30,350 15,943 51.42 30,075 15,465
Baseline fungal infection
Successful treatment 1.45 11,551 167 0.95 25,832 245
Mortality 0.00 0 0 0.00 0 0
Persistent baseline fungal infection 1.69 24,400 412 0.47 36,207 172
Total 100.00 – 23,835 100.00 – 26,358









































































































































Figure 2 Breakdown by category of cost per patient treated.
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clinicians from Turkey to determine the downstream ef-
fects of a treatment failure from the initial antifungal agent
and, in validating the assumptions and clinical pathway as
relevant and appropriate for the real-life setting within
Turkey is another advantage.
While the assumption of mortality and other initial ther-
apy failures occurring at the end of therapy may result in
an overestimation of the total cost per patient treated, its
overall impact on the study’s outcome is likely to be low
given mortality rates were relatively similar in those re-
ceiving LAmB or voriconazole as initial therapy, and the
assumption was applied equally across both agents with
respect to initial therapy failure. The other assumption of
requiring all patients with a baseline fungal infection that
fail initial therapy to be considered to have had persistent
fever should also have a minimal impact on the study’s
outcome as the patient numbers in the baseline fungal in-
fection branches, overall, was low.
The important differentiators of the Turkish healthcare
system compared to other systems is highlighted through
the results in this study; further emphasising that eco-
nomic data from different countries with different health-
care systems and policies cannot be readily generalise to
another country. Drug acquisition costs are relatively high
whilst the daily cost per hospital bed is low in comparison
to other western healthcare systems. A patient in the
Turkish healthcare setting has their expenses subsidized
by public insurance mechanisms, such as the SGK,
which now covers the majority of the population [20].
Out of pocket healthcare expenses in Turkey have been
reduced due to recent advances in the provision and fi-
nancing of healthcare services (17.4% out of pocket in
2008) [20]. The current study will assist in formulary
decision making in Turkey for the empirical use of vori-
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Figure 3 Probability of cost saving curve from the Monte Carlo
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building block in decisions made within other regions
with a similar healthcare system.
This study is different from earlier evaluations [11,21] in
its use of a large multinational, multicentre randomized
controlled trial [3] to populate the decision tree. Not only
does this allow for comparative ease of generalization
across similar healthcare systems, it allowed for theincor-
poration of the gold-standard 5-point composite outcome
measure. In the current study, systemic review of the lit-
erature for evidence of effectiveness was not conducted.
Whilst the randomized controlled study [3] used in the
present economic analysis concluded that voriconazole is
a suitable alternative to amphotericin B preparations, data
from the US Food and Drug Administration (FDA) sug-
gest that voriconazole was inferior to LAmB with respect
to overall success rates (23.7% versus 30.1%, respectively)
[22]. Had voriconazole been able to demonstrate non-
inferiority to LAmB, the result from this evaluation would
have economically favoured voriconazole. Hence the use
of the data from this failed non-inferiority study is not ex-
pected to have an impact on the conclusion reached in the
current economic evaluation.
Earlier economic analyses have utilized retrospective
chart reviews with some also having limited scope in
choice of both the definition of a successful outcome
and in the adverse outcomes of interest [11,13,23]. An
outcome that was investigated in several previous phar-
macoeconomic studies was quality-adjusted life years
(QALYs) [16,24,25]. This was not considered necessary or
an appropriate endpoint in the current evaluation for two
main reasons, namely the lack of a reasonable treatment
duration to assess a significant QALY change (the non-
inferiority trial used to populate the model did not include
any long-term survival data beyond 7 days), and that the
QALY gain/loss will be affected mainly by the patient’s
underlying condition (e.g. acute myeloid leukaemia) and
not by any effect from the choice of antifungal agent.
To assess the uncertainty involved in the determination of
fever resolution as a component of the composite outcome,
removing this scenario from the analysis was conducted.
This alternate scenario resulted in voriconazole being the
cost-effective alternative to LAmB for all three comparisons
(per patient treated, survival and success). The significance
of this finding is related to the difficulty in determining the
resolution of fever for the purposes of classifying therapy as
successful within a short time frame as seen in the pivotal
efficacy studies of empiric antifungal therapy [17].
Conclusion
The current study suggests that voriconazole would be the
economically favourable alternative to LAmB when used
as the initial agent in the empiric treatment of IFI. Our
economic conclusion was moderately robust and is sensi-
tive to treatment duration. The results from this
evaluation will have implications for formulary decision
making within Turkey and regions with a similar health-
care system, where treatment decisions in empiric antifun-
gal therapy based on the full economic and clinical
ramifications are not entirely clear.
Abbreviations
IFI: Invasive fungal infection; LAmB: Liposomal amphotericin B; TL: Turkish
Lira; ICU: Intensive care unit; G-CSF: Granulocyte colony-stimulating factor;
FBE: Full blood examination; CT: Computed tomography; SGK: Sosyal
Güvenlik Kurumu; BMT: Bone marrow transplant; MCS: Monte Carlo
simulation; QALY: Quality-adjusted life year; BFI: Breakthrough fungal
infection; PD: Premature discontinuation; PF: Persistent fever;
Vori: Voriconazole; NBI: No baseline infection.
Competing interests
This study was not funded by any pharmaceutical industry. DCMK has sat on
advisory boards for Pfizer and received research/travel support (not related
to the current work) from Pfizer, Roche, Merck, Novartis and Gilead Sciences.
ECD has sat on advisory boards for Biocodex International and
GlaxoSmithKline, received travel grants from Merck, GlaxoSmithKline, Pfizer
and Novartis and is a speaker for GlaxoSmithKline. ES has received travel
grants and honorarium as a speaker from Merck, Gilead Sciences, Pfizer and
Novartis. AK has received travel grants and honorarium as a speaker from
Merck, Gilead Sciences and Pfizer. SJT has no competing interests to declare.
Authors’ contributions
SJT was involved in the concept development, protocol design, analysis and
manuscript preparation. ES was involved in the concept development,
protocol design and manuscript review. AK was involved in the concept
development, protocol design and manuscript review. DA was involved in
the concept development, protocol design, analysis and manuscript review.
ECD was involved in the concept development, protocol design and
manuscript review. DCMK was involved in the concept development,
protocol design, analysis and manuscript preparation. All authors read and
approved the final manuscript.
Authors’ information
Ener C. Dinleyici and David CM Kong are co senior authors.
Acknowledgements
The authors acknowledge the support and insights provided by the panel of
expert clinicians in Turkey (Dr Omrum Uzun, Dr Alpay Azap, Dr Zeynep
Sahika Aki and Dr Ozlem Guzel Tunccan).
Author details
1Department of Pharmacy Practice and Administration, Ernest Mario School
of Pharmacy, Rutgers University, New Jersey, USA. 2Department of Infectious
Disease, Gazi University, Ankara, Turkey. 3Department of Pediatric Infectious
Disease, Hacettepe University, Ankara, Turkey. 4College of Pharmacy, Qatar
University, Doha, Qatar. 5Department of Pediatrics, Pediatric Intensive Care
and Pediatric Infectious Disease, Faculty of Medicine, Eskisehir Osmangazi
University, Eskisehir 26480, Turkey. 6Centre for Medicine Use and Safety,
Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
(Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
Received: 30 July 2013 Accepted: 21 November 2013
Published: 26 November 2013
References
1. Rüping M, Vehreschild J, Cornely O: Patients at high risk of invasive fungal
infections: when and how to treat. Drugs 2008, 68(14):1941–1962.
2. Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth W: Burden of
hospitalization of patients with Candida and Aspergillus infections in
Australia. Int J Infect Dis 2004, 8:111–120.
3. Walsh T, Pappas P, Winston D, Lazarus H, Petersen F, Raffali J, Yanovich S,
Stiff P, Greenberg R, Donowitz G, et al: Voriconazole compared with
liposomal amphotericin B for empirical antifungal therapy in patients
with neutropenia and persistent fever. N Engl J Med 2002, 346(4):225–234.
Turner et al. BMC Infectious Diseases 2013, 13:560 Page 8 of 9
http://www.biomedcentral.com/1471-2334/13/560
4. Maertens J, Marchetti O, Herbrecht R, Cornely O, Fluckiger U, Frere P,
Gachot B, Heinz W, Lass-Florl C, Ribaud P, et al: European guidelines for
antifungal management in leukemia and hematopoietic stem cell
transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow
Transplant 2011, 46(5):709–718.
5. Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C, Raad I, Rolston K,
Young J, Wingard J: Clinical practice guideline for the use of
antimicrobial agents in neutropenic patients with cancer: 2010 update
by the infectious diseases society of America. Clin Infect Dis 2011,
52(4):e56–93.
6. Kubiak D, Bryar J, McDonnell A, Delgado-Flores J, Mui E, Baden L, Marty F:
Evaluation of caspofungin or micafungin as empiric antifungal therapy
in adult patients with persistent febrile neutropenia: a retrospective,
observational, sequential cohort analysis. Clin Ther 2010, 32(4):637–648.
7. Walsh T, Teppler H, Donowitz G, Maertens J, Baden L, Dmoszynska A, Cornely
O, Bourque M, Lupinacci R, Sable C, et al: Caspofungin versus liposomal
amphotericin B for empirical antifungal therapy in patients with persistent
fever and neutropenia. N Engl J Med 2004, 351(14):1391–1402.
8. Brielmaier B, Casabar E, Kurtzeborn C, McKinnon P, Ritchie D: Early clinical
experience with anidulafungin at a large tertiary care medical center.
Pharmacotherapy 2007, 28(1):64–73.
9. Jeu L, Placenti F, Lyakhovetskiy A, Fung H: Voriconazole. Clin Ther 2003,
25(5):1321–1381.
10. Al-Badriyeh D, Liew D, Stewart K, Kong D: Cost-effectiveness evaluation of
voriconazole versus liposomal amphotericin B as empirical therapy for
febrile neutropenia in Australia. J Antimicrob Chemother 2009, 63(1):197–208.
11. Collins C, Stuntebeck E, DePestel D, Stevenson J: Pharmacoeconomic
analysis of liposomal amphotericin B versus voriconazole for empirical
treatment of febrile neutropenia. Clin Drug Invest 2007, 27(4):233–241.
12. Shehab N, DePestel D, Mackler E, Collins C, Welch K, Erba H: Institutional
experience with voriconazole compared with liposomal amphotericin B
as empiric therapy for febrile neutropenia. Pharmacotherapy 2007,
27(7):970–979.
13. Wingard J, Leather H, Wood C, Gerth W, Lupinacci R, Berger M, Mansley E:
Pharmacoeconomic analysis of caspofungin versus liposomal
amphotericin B as empirical antifungal therapy for neutropenic fever.
Am J Health Syst Pharm 2007, 64(6):637–643.
14. Turner S, Chen S, Slavin M, Kong D: Pharmacoeconomics of empirical
antifungal use in febrile neutropenic hematological malignancy and
hematopoietic stem cell transplant patients. Expert Rev Pharmacoecon
Outcomes Res 2013, 13(2):227–235.
15. Republic of Turkey-social security institution. http://www.sgk.gov.tr/wps/
portal/en?CSRT=16458562213556365941.
16. Bruynesteyn K, Gant V, McKenzi C, Pagliuca T, Poynton C, Kumar R, Jansen J:
A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin
B for treatment of suspected fungal infections in the UK. Eur J Haematol
2007, 78(6):532–539.
17. de Pauw B, Sable C, Walsh T, Lupinacci R, Bourque M, Wise B, Nguyen B-Y,
DiNubile M, Teppler H: Impact of alternate definitions of fever resolution on
the composite endpoint in clinical trials of empirical antifungal therapy for
neutropenia patients with persistent fever: analysis of results from the
caspofungin empirical therapy study. Transpl Infect Dis 2006, 8(1):31–37.
18. Al-Badriyeh D, Liew D, Stewart K, Kong D: Economic impact of
caspofungin as compared with liposomal amphotericin B for empirical
therapy in febrile neutropenia in Australia. J Antimicrob Chemother 2009,
63(6):1276–1285.
19. Al-Badriyeh D, Liew D, Stewart K, Kong D: Pharmacoeconomic analysis of
voriconazole vs. caspofungin in the empirical antifungal therapy of
febrile neutropenia in Australia. Mycoses 2012, 55(3):244–256.
20. Tatar M, Mollahaliloglu S, Sahin B, Aydin S, Maresso A, Hernandez-Quevado
C: Turkey, health system review. Health Syst Transit 2011, 13(6):1–184.
21. Romá-Sánchez E, Poveda-Andrés J, García-Pellicer J, Salavert-Lletí M, Jarque-
Ramos I: Cost-effectiveness analysis of the empirical antifungal strategy in
oncohaematological patients. Farm Hosp 2008, 32(1):7–17.
22. Powers J, Dixon C, Goldberger M: Voriconazole versus liposomal
amphotericin B in patients with neutropenia and persistent fever. N Engl
J Med 2002, 346(4):289–290.
23. Kaskel P, Tuschy S, Wagner A, Bannert C, Cornely O, Glasmacher A, Lipp H,
Ullmann A: Economic evaluation of caspofungin vs liposomal amphotericin
B for empirical therapy of suspected systemic fungal infection in the
German hospital setting. Ann Hematol 2008, 87(4):311–319.
24. Stam W, Aversa F, Kumar R, Jansen J: Economic evaluation of caspofungin
versus liposomal amphotericin B for empiric antifungal treatment in
patients with neutropenic fever in Italy. Value Health 2008, 11(5):830–841.
25. Naik S, Lundberg J, Kumar R, Sjolin J, Jansen J: Economic evaluation of
caspofungin versus liposomal amphotericin B for empirical antifungal
therapy in patients with persistent fever and neutropenia in Sweden.
Scand J Infect Dis 2011, 43(6-7):504–514.
doi:10.1186/1471-2334-13-560
Cite this article as: Turner et al.: Pharmacoeconomic evaluation of
voriconazole vs. liposomal amphotericin B in empiric treatment of
invasive fungal infections in Turkey. BMC Infectious Diseases 2013 13:560.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Turner et al. BMC Infectious Diseases 2013, 13:560 Page 9 of 9
http://www.biomedcentral.com/1471-2334/13/560
